This segment focuses on the research, development, and commercialization of disease-modifying treatments for Alzheimer's disease. Key activities include clinical trials for BAN2401 (Lecanemab), a humanized monoclonal antibody targeting amyloid-beta protofibrils, and the development of next-generation antibodies like BAN2401 Back-up. The segment also encompasses the development of imaging and biochemical biomarkers for early diagnosis and monitoring of disease progression. BioArctic's collaboration with Eisai is central to this segment, particularly for the global development and commercialization of Lecanemab. The goal is to provide effective therapies that slow or halt the progression of Alzheimer's, improving patient outcomes and quality of life. Future opportunities include expanding the use of Lecanemab to earlier stages of the disease and developing combination therapies for enhanced efficacy.

This segment is dedicated to developing innovative treatments for Parkinson's disease, focusing on therapies that target alpha-synuclein, a protein implicated in the disease's pathology. The lead asset in this segment is ABBV-0805, an alpha-synuclein antibody being developed in collaboration with AbbVie. Research efforts are directed towards understanding the role of alpha-synuclein in disease progression and developing antibodies that can effectively clear or neutralize toxic forms of the protein. The segment also includes the development of imaging and biochemical biomarkers for Parkinson's disease, aimed at improving diagnosis and monitoring treatment response. The objective is to provide disease-modifying therapies that can slow or halt the progression of Parkinson's, alleviating symptoms and improving the quality of life for patients. Future opportunities include exploring new targets and therapeutic modalities for Parkinson's disease, as well as developing personalized treatment approaches based on individual patient characteristics.

This segment encompasses BioArctic's broader research and development activities aimed at discovering and developing novel therapies for a range of neurodegenerative diseases. This includes preclinical research on new antibody candidates, biomarker development, and the exploration of innovative drug delivery technologies, such as blood-brain-barrier technology. The segment also focuses on identifying new therapeutic targets and developing platform technologies that can be applied to multiple neurodegenerative diseases. Collaborations with academic institutions and other companies are crucial to this segment, enabling BioArctic to access cutting-edge science and accelerate the development of new therapies. The ultimate goal is to build a robust pipeline of innovative treatments for neurodegenerative diseases, addressing unmet medical needs and improving the lives of patients.